Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies

Abstract

Introduction Drug repositioning is a strategy to identify a new therapeutic indication for molecules that have been approved for other conditions, aiming to speed up the traditional drug development process and reduce its costs. The high prevalence and incidence of coronavirus disease 2019 (COVID-19) underline the importance of searching for a safe and effective treatment for the disease, and drug repositioning is the most rational strategy to achieve this goal in a short period of time. Another advantage of repositioning is the fact that these compounds already have established synthetic routes, which facilitates their production at the industrial level. However, the hope for treatment cannot allow the indiscriminate use of medicines without a scientific basis. Results The main small molecules in clinical trials being studied to be potentially repositioned to treat COVID-19 are chloroquine, hydroxychloroquine, ivermectin, favipiravir, colchicine, remdesivir, dexamethasone, nitazoxanide, azithromycin, camostat, methylprednisolone, and baricitinib. In the context of clinical tests, in general, they were carried out under the supervision of large consortiums with a methodology based on and recognized in the scientific community, factors that ensure the reliability of the data collected. From the synthetic perspective, compounds with less structural complexity have more simplified synthetic routes. Stereochemical complexity still represents the major challenge in the preparation of dexamethasone, ivermectin, and azithromycin, for instance. Conclusion Remdesivir and baricitinib were approved for the treatment of hospitalized patients with severe COVID-19. Dexamethasone and methylprednisolone should be used with caution. Hydroxychloroquine, chloroquine, ivermectin, and azithromycin are ineffective for the treatment of the disease, and the other compounds presented uncertain results. Preclinical and clinical studies should not be analyzed alone, and their methodology’s accuracy should also be considered. Regulatory agencies are responsible for analyzing the efficacy and safety of a treatment and must be respected as the competent authorities for this decision, avoiding the indiscriminate use of medicines.

Antibiotic consumption in French nursing homes between 2018 and 2022: A multicenter survey

“…Azithromycin consumption increased sharply as its potential efficacy in COVID-19 treatment was studied at that time. 34 There was also a slight increase in ceftriaxone use in 2020, probably linked with prescriptions to cover the risk of infection by S. pneumoniae and S. aureus. 35 Indeed, other researchers reported that despite a low proportion (6.9%) of bacterial coinfection in patients hospitalized for COVID-19, 71.9% received antibiotics, often broad-spectrum agents such as third-generation cephalosporins.…”

Drug Repurposing and Lysosomal Storage Disorders: A Trick to Treat

“…Drug repositioning, or repurposing, is a strategy to identify new therapeutic uses for existing drugs [ 95 , 96 , 97 ], a promising approach with several limitations. Repositioned drugs are not so immediately applicable to therapy.…”

Chloroquine and Chemotherapeutic Compounds in Experimental Cancer Treatment

“…Both CQ and HCQ have been successfully used for the treatment of autoimmune diseases like rheumatic diseases [2,6] and systemic lupus erythematosus [6][7][8]. Recently, they have also been tested for the treatment and prophylactics of viral infections, including Zika virus [9,10], human immunodeficiency virus (HIV) [11,12], and COVID-19, although the obtained results were inconsistent or negligible and revealed many side effects [13,14].…”